Characteristics and clinical correlation of TIM-3 and PD-1/PD-L1 expressions in leukemic cells and tumor microenvironment in newly diagnosed acute myeloid leukemia

References

• Nixon NA, Blais N, Ernst S, et al. Current landscape of immunotherapy in the treatment of solid tumours, with future opportunities and challenges. Curr Oncol. 2018;25(5):e373–e384.
   PubMed Web of Science ®Google Scholar
• Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016;8(328):328rv4.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264.
   PubMed Web of Science ®Google Scholar
• Boddu P, Kantarjian H, Garcia-Manero G, et al. The emerging role of immune checkpoint based approaches in AML and MDS. Leuk Lymphoma. 2018;59(4):790–802.
   PubMed Web of Science ®Google Scholar
• Zajac M, Zaleska J, Dolnik A, et al. Expression of CD274 (PD-L1) is associated with unfavourable recurrent mutations in AML. Br J Haematol. 2018;183(5):822–825.
   PubMed Web of Science ®Google Scholar
• Chen X, Liu S, Wang L, et al. Clinical significance of B7-H1 (PD-L1) expression in human acute leukemia. Cancer Biol Ther. 2008;7(5):622–627.
   PubMed Web of Science ®Google Scholar
• Williams P, Basu S, Garcia-Manero G, et al. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer. 2019;125(9):1470–1481.
   PubMed Web of Science ®Google Scholar
• Mastaglio S, Wong E, Perera T, et al. Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy. Blood Adv. 2018;2(4):335–346.
   PubMed Web of Science ®Google Scholar
• Jia B, Wang L, Claxton DF, et al. Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients. Blood Cancer J. 2018;8(3):34.
   PubMedGoogle Scholar
• Tan J, Yu Z, Huang J, et al. Increased PD-1 + tim-3+ exhausted T cells in bone marrow may influence the clinical outcome of patients with AML. Biomark Res. 2020;8:6.
   PubMed Web of Science ®Google Scholar
• Dong W, Wu X, Ma S, et al. The mechanism of anti-PD-L1 antibody efficacy against PD-L1-negative tumors identifies NK cells expressing PD-L1 as a cytolytic effector. Cancer Discov. 2019;9(10):1422–1437.
   PubMed Web of Science ®Google Scholar
• Zhang L, Gajewski TF, Kline J. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood. 2009;114(8):1545–1552.
   PubMed Web of Science ®Google Scholar
• Berger R, Rotem-Yehudar R, Slama G, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res. 2008;14(10):3044–3051.
   PubMed Web of Science ®Google Scholar
• Daver N, Garcia-Manero G, Basu S, et al. Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study. Cancer Discov. 2019;9(3):370–383.
   PubMed Web of Science ®Google Scholar
• Das M, Zhu C, Kuchroo VK. Tim-3 and its role in regulating anti-tumor immunity. Immunol Rev. 2017;276(1):97–111.
   PubMed Web of Science ®Google Scholar
• Wolf Y, Anderson AC, Kuchroo VK. TIM3 comes of age as an inhibitory receptor. Nat Rev Immunol. 2020;20(3):173–185.
   PubMed Web of Science ®Google Scholar
• Dama P, Tang M, Fulton N, et al. Gal9/tim-3 expression level is higher in AML patients who fail chemotherapy. J Immunother Cancer. 2019;7(1):175.
   PubMedGoogle Scholar
• Tan J, Huang S, Huang J, et al. Increasing tim-3 + CD244+, tim-3 + CD57+, and tim-3 + PD-1+ T cells in patients with acute myeloid leukemia. Asia Pac J Clin Oncol. 2020;16(3):137–141.
   PubMed Web of Science ®Google Scholar
• Li C, Chen X, Yu X, et al. Tim-3 is highly expressed in T cells in acute myeloid leukemia and associated with clinicopathological prognostic stratification. Int J Clin Exp Pathol. 2014;7(10):6880–6888.
   PubMed Web of Science ®Google Scholar
• Haubner S, Perna F, Köhnke T, et al. Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. Leukemia. 2019;33(1):64–74.
   PubMed Web of Science ®Google Scholar
• Darwish NHE, Sudha T, Godugu K, et al. Acute myeloid leukemia stem cell markers in prognosis and targeted therapy: potential impact of BMI-1, TIM-3 and CLL-1. Oncotarget. 2016;7(36):57811–57820.
   PubMedGoogle Scholar
• Gonçalves Silva I, Gibbs BF, Bardelli M, et al. Differential expression and biochemical activity of the immune receptor tim-3 in healthy and malignant human myeloid cells. Oncotarget. 2015;6(32):33823–33833.
   PubMedGoogle Scholar
• Kikushige Y, Miyamoto T, Yuda J, et al. A TIM-3/gal-9 autocrine stimulatory loop drives self-renewal of human myeloid leukemia stem cells and leukemic progression. Cell Stem Cell. 2015;17(3):341–352.
   PubMed Web of Science ®Google Scholar
• Gonçalves Silva I, Yasinska IM, Sakhnevych SS, et al. The tim-3-galectin-9 secretory pathway is involved in the immune escape of human acute myeloid leukemia cells. EBioMedicine. 2017;22:44–57.
   PubMed Web of Science ®Google Scholar
• Kikushige Y, Shima T, Takayanagi S, et al. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell. 2010;7(6):708–717.
   PubMed Web of Science ®Google Scholar
• Kikushige Y, Miyamoto T. TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells. Int J Hematol. 2013;98(6):627–633.
   PubMed Web of Science ®Google Scholar
• Acharya N, Sabatos-Peyton C, Anderson AC. Tim-3 finds its place in the cancer immunotherapy landscape. J Immunother Cancer. 2020;8(1):e000911.
   PubMed Web of Science ®Google Scholar
• Wang Z, Chen J, Wang M, et al. One stone, two birds: the roles of tim-3 in acute myeloid leukemia. Front Immunol. 2021;12:618710.
   PubMed Web of Science ®Google Scholar
• Gleason MK, Lenvik TR, McCullar V, et al. Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. Blood. 2012;119(13):3064–3072.
   PubMed Web of Science ®Google Scholar
• Ndhlovu LC, Lopez-Vergès S, Barbour JD, et al. Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood. 2012;119(16):3734–3743.
   PubMed Web of Science ®Google Scholar
• Dao TN, Utturkar S, Lanman NA, et al. TIM-3 expression is downregulated on human NK cells in response to cancer targets in synergy with activation. Cancers (Basel). 2020;12(9):2417.
   Web of Science ®Google Scholar
• Folgiero V, Cifaldi L, Pira GL, et al. TIM-3/gal-9 interaction induces IFNγ-dependent IDO1 expression in acute myeloid leukemia blast cells. J Hematol Oncol. 2015;8:36.
   PubMed Web of Science ®Google Scholar
• Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.
   PubMed Web of Science ®Google Scholar
• Arber DA, Vardiman JW, Brunning RD, et al. Acute myeloid leukaemia and related precursor neoplasm. In: Swerdlow S, Campo E, Harris NL, Pileri SA, Jaffe E, Stein H, Thiele J, editors. World health organization classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: World Health Organization; 2017. p. 129–172.
   Google Scholar
• Rakova J, Truxova I, Holicek P, et al. TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients. Oncoimmunology. 2021;10(1):1889822.
   PubMed Web of Science ®Google Scholar
• Yang C, Siebert JR, Burns R, et al. Heterogeneity of human bone marrow and blood natural killer cells defined by single-cell transcriptome. Nat Commun. 2019;10(1):3931.
   PubMedGoogle Scholar
• Baragaño Raneros A, López-Larrea C, Suárez-Álvarez B. Acute myeloid leukemia and NK cells: two warriors confront each other. Oncoimmunology. 2019;8(2):e1539617.
   PubMed Web of Science ®Google Scholar
• Xu L, Huang Y, Tan L, et al. Increased tim-3 expression in peripheral NK cells predicts a poorer prognosis and tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma. Int Immunopharmacol. 2015;29(2):635–641.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Li Y, Lian J, et al. TNF-α-induced tim-3 expression marks the dysfunction of infltrating natural killer cells in human esophageal cancer. J Transl Med. 2019;17(1):165.
   PubMedGoogle Scholar
• Kim N, Kim HS. Targeting checkpoint receptors and molecules for therapeutic modulation of natural killer cells. Front Immunol. 2018;9(2041):2041.
   PubMedGoogle Scholar
• Xu L, Xu J, Ma S, et al. High tim-3 expression on AML blasts could enhance chemotherapy sensitivity. Oncotarget. 2017;8(60):102088–102096.
   PubMedGoogle Scholar
• Hsu J, Hodgins JJ, Marathe M, et al. Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade. J Clin Invest. 2018;128(10):4654–4668.
   PubMed Web of Science ®Google Scholar
• Quatrini L, Mariotti FR, Munari E, et al. The immune checkpoint PD-1 in natural killer cells: expression, function and targeting in tumour immunotherapy. Cancers (Basel). 2020;12(11):3285.
   PubMed Web of Science ®Google Scholar
• Judge SJ, Dunai C, Aguilar EG, et al. Minimal PD-1 expression in mouse and human NK cells under diverse conditions. J Clin Invest. 2020;130(6):3051–3068.
   PubMed Web of Science ®Google Scholar